{"classes":[{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"6.14","upperLimit":"6.14","value":"6.14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Duration of response was defined as the time from the date of the first response (CR/PR, using RECIST version 1.1 guidelines) to disease progression for participants with a confirmed CR or PR. Participants who did not have disease progression or had not died were censored at the time of their last disease assessment or at time of start of new anticancer therapy, whichever occurred first. (For Phase 2 neuroblastoma patients who had both RECIST version 1.1 and Curie Score tumor evaluations, both tumor responses results were considered and an overall response was derived.)","dispersionType":"Full Range","groups":[{"description":"Participants with Ewing's sarcoma: nab-paclitaxel at the RP2D (240 mg/m\\^2 in participants weighing \\> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.","id":"OG000","title":"Phase 2: Ewing's Sarcoma"},{"description":"Participants with neuroblastoma: nab-paclitaxel at the RP2D (240 mg/m\\^2 in participants weighing \\> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.","id":"OG001","title":"Phase 2: Neuroblastoma"},{"description":"Participants with rhabdomyosarcoma: nab-paclitaxel at the RP2D (240 mg/m\\^2 in participants weighing \\> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.","id":"OG002","title":"Phase 2: Rhabdomyosarcoma"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Population: participants (with response) who met eligibility criteria for Phase 2, completed ≥ 1 dose of study drug, and had baseline and ≥ 1 postbaseline efficacy assessment if having not discontinued the investigational product prior to postbaseline efficacy assessment due to disease progression or systematic deterioration.","reportingStatus":"POSTED","timeFrame":"Median treatment duration in Phase 2 per group: Ewings Sarcoma = 14 weeks (3-31), Neuroblastoma = 7 weeks (3-23), Rhabdomyosarcoma = 5 weeks (1-13). Participants were followed until disease progression (if applicable) up to a maximum of 100.3 weeks.","title":"Phase 2: Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"weeks"}